In January 2020, we issued and sold 5,824,729 common shares and, in lieu of common shares, 1,075,271 pre-funded warrants to purchase common shares in a registered public offering, at prices to the public of $46.50 per common share and $46.4999 per pre-funded warrant,
respectively (the January 2020 Public Offering). Baker Brothers Life Sciences, L.P. and 667, L.P., for which Baker Bros. Advisors LP serves as investment adviser, purchased 986,416 and 88,855
pre-funded warrants in the January 2020 Public Offering, respectively. Dr. Neu, who joined our Board in March 2020, was an employee of Baker Bros. Advisors LP at the time of the January 2020 Public
Offering and remained an employee of Baker Bros. Advisors LP until January 2021. Mr. Cox also purchased 7,500 common shares in the January 2020 Public Offering.
In March 2020, we granted to Baker Brothers Life Sciences, L.P. and 667, L.P. certain registration rights requiring us, upon request delivered by such persons
on or after April 22, 2020 and subject to certain terms and conditions, to register the resale by such persons of the common shares held by them (the Registration Rights Agreement).
In December 2020, we filed a prospectus supplement registering for resale, from time to time, up to 6,950,433 of our common shares held by Baker Brothers Life
Sciences, L.P. and 667, L.P. pursuant to the Registration Rights Agreement.
Indebtedness of Directors, Executive Officers and Employees
None of our directors, executive officers, employees, former directors, former executive officers or former employees, and none of their associates, is
indebted to us or another entity whose indebtedness is the subject of a guarantee, support agreement, letter of credit or other similar agreement or understanding provided by us.
Policy Regarding Related Party Transactions
All
transactions between us and our officers, directors, principal shareholders and their affiliates must be approved by the audit committee, or a similar committee consisting of entirely independent directors.
Requirements under the Business Corporations Act (British Columbia)
Pursuant to the BCBCA, directors and officers are required to act honestly and in good faith with a view to the best interests of the Company. Under the BCBCA,
subject to certain limited exceptions, a director who holds a disclosable interest in a material contract or transaction into which we have entered or propose to enter shall not vote on any directors resolution to approve the contract or
transaction. A director or officer has a disclosable interest in a material contract or transaction if the director or officer:
|
|
|
is a party to the contract or transaction;
|
|
|
|
is a director or officer, or an individual acting in a similar capacity, of a party to the contract or
transaction; or
|
|
|
|
has a material interest in a party to the contract or transaction.
|
Generally, as a matter of practice, directors or officers who have disclosed a material interest in any contract or transaction that our Board of Directors is
considering will not take part in any board discussion respecting that contract or transaction. If such directors were to participate in the discussions, they would abstain from voting on any matters relating to matters in which they have disclosed
a disclosable interest.
Interests of Management and Others in Material Transactions
Other than as described elsewhere in this proxy statement, there are no material interests, direct or indirect, of any of our directors or executive officers,
any shareholder that beneficially owns, or controls or directs (directly
27